<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867161</url>
  </required_header>
  <id_info>
    <org_study_id>146/20</org_study_id>
    <nct_id>NCT04867161</nct_id>
  </id_info>
  <brief_title>Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients</brief_title>
  <acronym>SUPER-HI</acronym>
  <official_title>Superinfection and Hyperinflammatory Phenotype in COVID-19 (Coronavirus Disease 2019) Pneumonia Patients (SUPER-HI) - Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brno University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from COVID-19 (Coronavirus Disease 2019) pneumonia are prone to bacterial&#xD;
      and mycotic superinfection. According to existing evidence, the prevalence of superinfection&#xD;
      is about 8% to 14% (95% CI 5-26%). However, the percentage of patients treated for&#xD;
      superinfection is as high as 80%. There can be multiple reasons for this difference.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inflammatory markers, such as C-reactive protein (CRP), procalcitonin (PCT), presepsin&#xD;
      (PSP), interleukin-6 (IL-6) frequently used as diagnostic tools in COVID-19 (Coronavirus&#xD;
      Disease 2019), are usually increased in these patients. This increase is a result of&#xD;
      activation of systemic inflammatory cascade, part of COVID-19 pathophysiologic pathway. This&#xD;
      can escalate to state known as COVID-19 associated hyperinflamation (COV-HI). In addition,&#xD;
      current diagnostic tools for diagnosing HAP/VAP (hospital-acquired pneumonia and&#xD;
      ventilator-associated pneumonia) are often limited in patients with COVID-19 pneumonia. The&#xD;
      current method of choice for superinfection diagnosing is BAL (Bronchoalveolar Lavage). The&#xD;
      COV-HI phenotype (COV-HI: CRP &gt; 150 mg/L, or doubling within 24 h from greater than 50 mg/L,&#xD;
      or ferritin concentration &gt; 1500 ug/L) is associated with significantly worse course of&#xD;
      illness and higher mortality rates. These inflammatory markers may be used preferentially as&#xD;
      prognostication tools, not bacterial superinfection markers. The intention of this project is&#xD;
      to investigate the role of currently used inflammatory biomarkers. Or eventually, to discover&#xD;
      new parameters associated with superinfection proven by BAL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory markers dynamics in participants with superinfection in COVID-19 pneumonia</measure>
    <time_frame>28 days</time_frame>
    <description>To investigate the role of inflammatory markers (CRP, PCP, PSP, IL-6) as diagnostic tools for superinfection in COVID-19 pneumonia patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality from any cause</measure>
    <time_frame>28, 60, 90, 180, 360 days</time_frame>
    <description>To assess the association between hyperinflammatory phenotype and course of illness and mortality rates in COVID-19 pneumonia patients.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <condition>Superinfection Lung</condition>
  <arm_group>
    <arm_group_label>Patients with COVID-19 pneumonia without superinfection</arm_group_label>
    <description>Patients with confirmed COVID-19 pneumonia not fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with COVID-19 pneumonia with superinfection</arm_group_label>
    <description>Patients with confirmed COVID-19 pneumonia fulfilling criteria for diagnosis HAP/VAP (International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia )</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Inflammatory markers sampling</intervention_name>
    <description>Laboratory sampling:&#xD;
Haematology: complete blood count, reticulocytes, IFP, PT, aPTT, fibrinogen, D-dimer Biochemical profile: urea, creatinine, bilirubin, ALT, AST, GGT, CK, LD, ferritin, troponin Inflammation markers IL-6, PCT (procalcitonin), CRP (C-reactive protein), PSP (presepsin)&#xD;
BALF (bronchoalveolar lavage fluid) processing protocol:&#xD;
microbiology: microscopic examination, standard cultivation test&#xD;
biochemistry: albumin, total protein&#xD;
Pathology: cytology&#xD;
PCR:&#xD;
a. Multiplex PCR b. SARS-CoV-2 RNA load</description>
    <arm_group_label>Patients with COVID-19 pneumonia with superinfection</arm_group_label>
    <arm_group_label>Patients with COVID-19 pneumonia without superinfection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum samples and bronchoalveolar fluid samples are stored in aliquots&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 diagnostics:&#xD;
&#xD;
        PCR test from nasopharyngeal swab or tracheal aspirate plus Chest X-ray/Computer tomography&#xD;
        signs of pneumonia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. admission on ICU&#xD;
&#xD;
          2. age more than 18 years&#xD;
&#xD;
          3. COVID-19 pneumonia criteria fulfilled&#xD;
&#xD;
        Exclusion Criteria: none&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Mal치ska</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brno University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Mal치ska</last_name>
    <phone>+420532232009</phone>
    <email>jan.malaska@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Mal치ska</last_name>
      <phone>+420723784101</phone>
      <email>jan.malaska@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jan Sta코ek</last_name>
      <phone>+420532232009</phone>
      <email>janstasek@centrum.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530. Review.</citation>
    <PMID>32358954</PMID>
  </reference>
  <reference>
    <citation>Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020 Aug;81(2):266-275. doi: 10.1016/j.jinf.2020.05.046. Epub 2020 May 27.</citation>
    <PMID>32473235</PMID>
  </reference>
  <reference>
    <citation>Keddie S, Ziff O, Chou MKL, Taylor RL, Heslegrave A, Garr E, Lakdawala N, Church A, Ludwig D, Manson J, Scully M, Nastouli E, Chapman MD, Hart M, Lunn MP. Laboratory biomarkers associated with COVID-19 severity and management. Clin Immunol. 2020 Dec;221:108614. doi: 10.1016/j.clim.2020.108614. Epub 2020 Oct 22.</citation>
    <PMID>33153974</PMID>
  </reference>
  <reference>
    <citation>Manson JJ, Crooks C, Naja M, Ledlie A, Goulden B, Liddle T, Khan E, Mehta P, Martin-Gutierrez L, Waddington KE, Robinson GA, Ribeiro Santos L, McLoughlin E, Snell A, Adeney C, Schim van der Loeff I, Baker KF, Duncan CJA, Hanrath AT, Lendrem BC, De Soyza A, Peng J, J'Bari H, Greenwood M, Hawkins E, Peckham H, Marks M, Rampling T, Luintel A, Williams B, Brown M, Singer M, West J, Jury EC, Collin M, Tattersall RS. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020 Oct;2(10):e594-e602. doi: 10.1016/S2665-9913(20)30275-7. Epub 2020 Aug 21.</citation>
    <PMID>32864628</PMID>
  </reference>
  <reference>
    <citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12. Review. Erratum in: Lancet Infect Dis. 2020 Oct;20(10):e250.</citation>
    <PMID>32539990</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brno University Hospital</investigator_affiliation>
    <investigator_full_name>Jan Malaska</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>superinfection</keyword>
  <keyword>inflammatory markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Superinfection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

